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Aim: Consistent expansion of primary human endothelial cells in vitro is critical in the development of
engineered tissue. A variety of complex culture media and techniques developed from different basal media
have been reported with alternate success. Incongruous results are further confounded by donor-to-donor vari-
ability and cellular source of derivation. Our results demonstrate how toovercome these limitations using soluble
CD54 (sCD54) as additive to conventional culture medium.
Methods and results: Isolated primary fragment of different vessel types was expanded in Ham's F12 DMEM,
enriched with growth factors, Fetal Calf Serum and conditioned medium of Human Umbilical Vein Endothelial
Cells (HUVEC) collected at different passages. Cytokine content of culturemediawas analyzed in order to identify
the soluble factors correlating with better proliferation proﬁle. sCD54was found to induce the in vitro expansion
of human endothelial cells (HECs) independently from the vessels source and even in the absence of HUVEC-
conditioned medium. The HECs cultivated in the presence of sCD54 (50 ng/ml), resulted positive for the expres-
sion of CD146 and negative for CD45, and lower ﬁbroblast contamination. Cells were capable to proliferate with
an S phase of 25%, to produce vascular endothelial growth factor, VEGF, (10 ng/ml) and to give origin to vessel-
like tubule in vitro.
Conclusion: Our results demonstrate that sCD54 is an essential factor for the in-vitro expansion of HECs without
donor and vessel-source variability. Resulting primary cultures can be useful, for tissue engineering in regenera-
tive medicine (e.g. artiﬁcial micro tissue generation, coating artiﬁcial heart valve etc.) and bio-nanotechnology
applications.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
CD54 is amajor functionalmolecule expressed inHuman Endothelial
Cells (HECs). Membrane-bound CD54 (mCD54) on the surface of HECs
acts as a co-stimulatory/adhesion molecule toward T cell adhesion
and activation through binding with lymphocyte function associated
antigen 1 (LFA-1) [1,2]. Soluble CD54 (sCD54), derived from
membrane-CD54 by shedding, is produced by a variety of different
cells including human umbilical vessel endothelial cell (HUVEC),oratory, Department of Health
raecia” 88100 Catanzaro, Italy.
land Ltd. This is an open access articlhuman saphenous vein endothelial cell, human aortic smooth muscle
cell, melanoma cells and hematopoietic cell lines. sCD54 is present in
normal human serum at concentrations between 100 and 450 ng/ml
[3]. This concentration increases in the sera of patients with lymphoma,
leukemia, hypertension, and hepatitis [4–6]. It has also been described
that sCD54 can stimulate chemotactic HEC migration, HEC tube forma-
tion on Matrigel, sprouting in an aortic ring assay and angiogenesis in
chick chorioallantonic membrane assays [7].
In our study, for the ﬁrst time, we report a protocol that uses sCD54
as additive to promote the in vitro expansion of HECs. Human endothe-
lial cells can be used for various applications includingmolecular proﬁl-
ing (e.g., transcriptomics [8], proteomics, micro RNA analysis, genomic
analysis [9]) as well as cell culture (e.g., generation of cell lines through
immortalization [10], in vitro drug testing [11], tissue engineering [12]).e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of cellular andmolecularmechanisms underlying involvement of endo-
thelial cells in wound healing, atherosclerosis, thrombosis, and abnor-
mal angiogenesis [13–16]. Many publications showed that human
differentiated endothelial cells can be isolated from different arterial/
venous biopsy. Van Beijnum, JR et al. (2008) [17] isolated HECs by
making a single-cell suspension of tissue by mechanical disruption
and enzymatic digestion. After tissue disaggregation, HECs are puriﬁed
by immunomagnetic separation or using high-speed cell sorting. Simi-
larly, Yu SY et al. [18] showed a method to obtain and identify human
coronary artery-derived endothelial cells during routine percutaneous
coronary interventions by immunomagnetic bead isolation technique.
However, incomplete purity of resulting endothelial cells and poor
yield due to removal of cell surface epitopes during dissociation are
strong limitations of this approaches. The protocol of HEC isolation
presented here is standardized andwithout donor and source variability
guarantees a good yield of CD146 positive and CD45 negative HECs.
2. Materials and methods
2.1. Patients enrolled
A cohort of patients was involved, undergoing coronary artery
bypass graft surgery (CABG) with pedicle left internal mammary artery,
(LIMA), performed on pump in the Cardiovascular Surgery of the
Medicine and Surgery Sciences Department of Salvatore Venuta
Campus of the University “Magna Graecia” of Catanzaro in Italy. Each
patient signed an informed consent, approved by our bioethical
commission (Ethics Committee of the “Mater Domini”UniversityHospi-
tal, reference for University Magna Graecia of Catanzaro, approved
document number 2012.65). All surgical procedures were performed
following standard protocols. The LIMA was harvested semi-
skeletonized i.e. with the concomitants veins but without the thoracic
fascia. Low voltage (20 mV) electro-cautery was always used for the
dissection, and the side branches were always clipped on the arterial
side.
2.2. Procedure of isolation
Biopsied vessels were immediately immersed in standard medium
with complete F-12K growth medium, 0.1 mg/ml Heparin, 0.03 mg/ml
endothelial cell growth supplement (ECGS), fetal bovine serum (FBS)
10%, Gentamicin 3%, and Amphotricin D 3% and rinsed with phosphate
buffered saline (PBS). The vessel fragment was placed in a culture
dish, the adipose tissue was removed and the vessel was de-
endothelialized cutting lengthwise and the remaining layer was cut
into 1.5 mm pieces. Each piece was placed in a 96-well culture plate
and 50 μl of fresh F-12K complete growth medium, supplemented
with 5 μl (1:10) of ECGS. Successively cells were incubated at 37 °C
and 5% CO2.
2.3. HUVEC conditioned media
Conditioned culture medium (CCM) was obtained from 70% conﬂu-
ent HUVEC cultured for 48 h in fresh medium. The CCM collection was
performed after the ﬁrst subculture and successively after fourth (p4)
and sixth (p6) sub-cultivations respectively. The unconditioned culture
medium served as control.
2.4. Characterization of HUVEC CCM
Analysis of human cytokines of CCM was performed with Proteome
Proﬁler RD system, (Catalogue number ARY005). For the experiments
involving conditioned media, media from 10- to 14-day-old cultures
were collected and ﬁltered with 0.2-μm ﬁlters. The protein concentra-
tion of conditioned media was determined with the Bradford proteinassay (Bio-Rad Protein Assay Dye Reagent Concentrate, Bio-Rad),
using bovine gamma globulin as the standard. The protein concentra-
tion ranged from 50 to 70 μg/μl. Analyses of collected sample were per-
formed as reported in literature [19]. Cytokine array data on developed
X-ray ﬁlmwere quantiﬁed scanning the ﬁlmwith a transmission-mode
scanner and analyzing the array image ﬁle using image analysis Shion
Corp software. Each array contains internal control spots, two positive
and one negative.
2.5. Antibodies and reagents
Monoclonal anti-human ICAM/CD54 (mouse IgG1, clone BBIG-I1)
and related isotype control were purchased from, R&D Systems, Inc.
When needed, anti-CD54 and isotype control were added at the
same concentration (15 ng/ml) to the Ham's F-12 medium (GIBCO)
containing 0.25% BSA (Sigma-Aldrich, France). Recombinant human
ICAM-1/CD54 (murine myeloma cell line, NSO-derived; Accession
#CAA30051), CD146, KDR and CD31 were purchased from R&D
Systems, Inc.; CD45 was purchased from AbD Serotec, CD34 and CD14
were purchased from Becton Dickinson Pharmingen, and ﬁbronectin
was purchased from Southern Biotech. Anti-alpha smooth muscle
Actin antibody was purchased from Abcam.
2.6. Cell cultures
Primary cell cultures were established from endothelial biopsy.
Endothelial cells were seeded on culture dishes in standard medium
with complete F-12K growth medium (Gibco, Catalogue number
21765-029), 0.1 mg/ml Heparin, 0.03 mg/ml endothelial cell growth
supplement (ECGS) (Sigma-Aldrich, France. Catalogue number
E0760), FBS 10%, Gentamicin 3%, and Amphotricin D 3% (GIBCO). The
cell cultures were maintained at a conﬂuence of 75% before use. More-
over, one thousand cells for each patient, were plated in 96-well ﬂat-
bottom plates with sphere growth medium D-MEM/F-12 (0.1 mg/ml
Heparin, 25 ng/ml FGF, 50 ng/ml EGF, BSA1%, Penicillin Streptomycin
1% (GIBCO)).
2.7. Immunoﬂuorescence and ﬂowcytometry
2.7.1. Immunoﬂuorescence
Slides ﬁxed in formaldeyde 2% were dipped in working solution
(WS) PBS 0.1% (GIBCO), BSA 0.2% (Sigma-Aldrich).Monoclonal antibod-
ies diluted inWS (1:100) were added, and the slides were incubated for
60 min at room temperature (RT). The slides were washed with three
changes of PBS for 5 min and then mounted with coverslip using aque-
ous mountingmedium 90% of glycerol in PBS. Cells were observed with
an Inverted Confocal Microscopy Nikon TE2000 using 408 nm (blue
ﬂuorescence, DAPI excitation), 543 nm (red ﬂuorescence, ﬂuorochrome
PE) and 488 nm (green ﬂuorescence, ﬂuorochrome FITC) excitation
length. The microscope is located within a clean room (class 1000,
T=25 °C). Themagniﬁcation usedwas of 20× and 40×with numerical
aperture of the objective lens of 0.45 and 0.75 respectively. Imageswere
acquired through the camera (QICAM model FAST 1394), using the
NIKON EZC1 software, n.3.7 and merged using Adobe Photoshop
software (v7.0).
2.7.2. Flow cytometry
The cells were washed in PBS, and incubated in PBS + 10 mmol
EDTA at 37 °C for 15 min. Cell suspension was centrifuged. Following,
the cells were incubated at 4 °C with primary antibodies diluted
1:100. After the staining, cells were washed and resuspended in PBS
and 1% FCS at a ﬁnal concentration of 1.5 × 105 cells/ml. Acquisition
was performed with FACSCanto (Becton Dickinson, San Diego, CA)
and analysis was done with Cellquest software. S-phase analysis: was
performed as reported in literature [20]. Brieﬂy, 1.5 × 105 cells were
washed with cold PBS 1X and ﬁxed with 70% ethanol at −20 °C
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2 mg/ml RNAse A (Sigma-Aldrich) and kept at 37 °C for 60 min. Pellets
were resuspended in staining buffer (500 μl PBS containing 50 μg/ml of
Propidium Iodide) and incubated at RT for 60 min. DNA content was
analyzed by the FACSCanto. The cell-cycle phase distribution was
determined with Modﬁt 3.1 Software (Becton and Dickinson)
2.8. ELISA-based VEGF quantiﬁcation
Antibodies anti hVEGF (R&D Systems) and a detection antibody
conjugated to horseradish peroxidase (HRP) (Southern Biotech) were
used to develop ELISA test. The substrate for peroxidase labels proce-
dure was included in the kit Super signal ELISA Pico Chemiluminescent
Substrate (Thermo Scientiﬁc). The intensity of signals was proportional
to the amount of secondary antibody. Relative light units were
measured in a luminometer (Perkin Elmer, Victor 3) operating at
425 nm wavelength. VEGF value was determined on the basis of three
standard curves media realized with know VEGF quantities.
2.9. Matrigel seeding
Conditioned media were collected, centrifuged, and transferred to
fresh tubes from HUVEC cell lines at 80% of conﬂuence growing in
RPMI640 (GIBCO). The endothelial cells at 70% of conﬂuence, were
trypsinized, washed and seeded in each well with conditioned culture
medium on growth factor-containing BD Matrigel (Basement
Membrane Matrix, Becton Dickinson) in a 24-well-plate, and incubated
in 5% CO2 at 37 °C at density of 8 × 105ml. Tube formationwas detected
with an inverted light optical microscope (Leica). Three random ﬁelds
per well were examined at 20× magniﬁcation, and the values were
averaged. The pattern/value association criteria for tube formation are:Fig. 1. Cultivated human endothelial cells. Adherent endothelial cells were obtained from arte
collected at passage 4 (p4) of HUVEC cultivation. Immunostaining for CD146 (C–E) on adher
obtained from artery biopsy. DNA staining with DAPI (4,6-diamidino-2-phenylindole) was use0 = individual cells, well separated; 1 = cells beginning to migrate
and align themselves; 2 = capillary tubes visible without sprouting;
3 = sprouting of new capillary tubes; 4 = closed polygons beginning
to form; and 5 = complex mesh like structures developing. Each well
was photographed using an inverted optical microscope with a digital
camera. The images were taken at 20 and 40× magniﬁcation and the
total lengths of the tubes were measured with Image J (Image Process-
ing Analysis in Java, ver. 1.42; developed by Wayne Rasband, National
Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/
ij/index.html).
2.10. Statistical analysis
All results are reported as mean ± standard error of the mean
(SEM). Data were analyzed using Student's t test. A P value of less
than 0.05 was considered signiﬁcant and a P value of less than 0.01
was considered highly signiﬁcant. IBM SPSS Statistics 20 software and
Microsoft® Ofﬁce Excel 2010 were used for data analysis and graphing.
3. Results
3.1. Expansion of human endothelial cells isolated from vessel walls in the
presence of a speciﬁc HUVEC-conditioned medium
Twelve man volunteers from 50 to 83 years old (68 ± 3) were
involved, undergoing CABG with pedicle LIMA. Their characteristics
are reported in Supplemental Table 1. None of the collected radial arter-
ies and veins (diameter 8.1 ± 0.8 mm), were affected by intimae thick-
ening and all artery walls were disease free (atherosclerosis or medial
calciﬁcation). Freshly collected cells, from internal mammary artery
(Fig. 1A) and vein biopsy (Fig. 1B), were negative for CD45 markerry (A) and vein (B) biopsy. Cells were cultivated in the presence of conditioned medium
ent cells demonstrates the presence of CD146-positive cells within adherent monolayer
d to evidence nuclei distribution (E). Scale bars: A and B 100 μm; C, D, and E 20 μm.
Fig. 2. Long-lived endothelial cultures treated with HUVEC-conditioned medium (CM)
collected at different subcultures. Cell density measured as number of cells for mm2
(y-axis) increases in relation to the time of cultivation (day) (x-axis), in the presence of
conditioned medium collected at passage p1 (CMP1), p4 (CMP4) and p6 (CMP6) of
HUVEC cultures. The best increase in cell density was registered in the culture treated
with the CM collected at fourth passages of HUVEC sub cultivation (p4).
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7% markers. Immunostaining on adherent cells of nuclei and CD146
was reported in Fig. 1(C–E). In order to describe growth under the dif-
ferent culture condition, we counted the number of cells. We detected
1.5 × 103 cells/mm2 for up to 5 passages without losing the proliferative
capacity with the 1:1 addition of the conditioned medium collected atFig. 3. Cytokine proteomic array of HUVEC-conditioned medium. HUVEC conditioned medium
passageHUVECp6 (C) andwas analyzed for the presenceof soluble factors.Membrane array sho
in duplicated. Internal positive and negative spots control were reported at the top and to thedifferent passages (p1, p4, p6) of HUVEC cultures to standard medium.
The cells are long-lived in culture and have different capacities of expan-
sion. Highest cell numbers were generated with conditioned medium
collected at p4 of HUVEC cultivation. The cell density calculated in
terms of cell number/mm2 is shown in the graphic of Fig. 2. After the
second replanting, cells were negative for hematopoietic lineage
markers (CD34, CD45, CD133) and monocyte markers (CD14) and
positive for endothelial markers such as CD146 45 ± 5%, CD31 41 ±
2%, KDR 22 ± 6%. Flow cytometry of cells at the third passages showed
a stable phenotype and the ﬁbronectin expression was of 3 ± 1%.
Remaining cultivated cells have shown immunoﬂuorescence positivity
for α-actin antibody, suggesting a smooth muscle cellular phenotype.3.2. Characterization of HUVEC-conditioned medium paracrine effects
Conditioned culture medium obtained from 70% conﬂuent HUVEC
cultured 48 h in fresh medium, was collected after the ﬁrst subculture
and successively after p4 and p6 subcultivations respectively, and
was added to standard medium to cultivate endothelial cells. The
results of the cytokine array of the three medium showed a different
composition for qualitative and quantitative difference, as shown in
Fig. 3(A–C). The paracrine activity of the HUVEC was characterized by
the production of CCL1, CD54, IL-6, CXCL8, IL23, IL27, MCP-1, MIF, and
Serpin E1. The production of CD54 is restricted to themedium collected
after the fourth passage indicating this molecule as a good candidate to
explain the efﬁcacy of p4 conditioned medium in sustaining cell
proliferation.was collected after ﬁrst passage HUVEC p1 (A), fourth passage HUVEC p4 (B), and sixth
ws the spot corresponding to the reaction of soluble cytokine and relative antibody printed
right of each membrane.
Fig. 4. Cell density of endothelial cells cultivated in the presence of soluble CD54. Endothe-
lial cells cultivated in the presence of soluble CD54 (sCD54) were expanded for ﬁve splits.
After the ﬁrst (p1), second (p2) and ﬁfth (p5) passages (as shown in the x-axis) the
cellular densities were measured (y-axis) and compared between different growing
conditions: in the presence of sCD54 alone, resulting in higher propagation rate, than
cell culture treated with HUVEC-conditioned medium collected at p4 (CMP4) alone.
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endothelial cells with in vitro addition of soluble CD54
Endothelial cells cultivated in the presence of sCD54 added at the
concentration of 50 ng/ml to standardmedium are long-lived in culture
and have a signiﬁcant capacity of expansion. The dosage of 50 ng/ml
was identiﬁed examining a dose–response curve; corresponding doses
usedwere 10, 30, 50, 70, and 80 ng/ml and cellular densitywas checked.
On day 3 complete medium exchanges were performed and cells still
ﬂoating in the supernatant were discarded. Cell proliferation appearedFig. 5.Capillary density. Tube formation occurred through anordered sequence of events andwa
align themselves to close polygons beginning (B) to form complete tubules (C) of endothelial ce
quantitative analysis of tube formation area; in the x-axiswas reported capillary density in the p
against CD54 at the concentration of 15 ng/ml (y-axis). Scale bars: 200 μm.to be exponential from the third day. The S-phase at ﬁfth passage was
of 25 ± 2% in the presence of sCD54 versus 19 ± 2% of corresponding
culture in the presence of HUVEC-conditioned medium p4. Cell density
calculated as number of cells per mm2 is shown in Fig. 4. The expansion
observed after the third passage continued in similar fashion after
the ﬁfth passage. In particular the cellular density registered in the pres-
ence of sCD54 after the ﬁrst passage was of 9 ± 1 × 103 cells/mm2,
after the third of 24 ± 9 × 103 cells/mm2, after the ﬁfth of 73 ±
12 × 103 cells/mm2. Signiﬁcant difference was observed comparing
the cellular density at the ﬁfth passage of endothelial cells cultivated
with sCD54 and Huvec-p4 medium: p = 0.008. After the second
replanting, cultivated cells were positive for endothelial markers as
CD146 45 ± 5%, CD31 41 ± 2%, and KDR 22 ± 6%. Flow cytometry of
cells at the third passages showed a stable phenotype and the ﬁbronec-
tin expression was of 1.3 ± 1%. Inhibition assay using antibody against
CD54 (15 ng/ml) and IgG 1 (15 ng/ml) as isotype control was used
and conﬁrms that in the absence of CD54 or in the presence of reciprocal
monoclonal antibody, we didn't obtain endothelial colony structure, as
shown in histogram of Fig. 5.
3.4. Soluble CD54 preserves long-term in vitro differentiation and promote
self-organization vessel-model
The ability to form sphere was developed to test the power of cell
replacement. Moreover, we tested endothelial functionality through
VEGF production and vessel-like structure in vitro generation. No
difference was registered in terms of ability to form sphere (Fig. 1
Supplementary). Different behavior was observed in terms of VEGF
production (Fig. 2 Supplementary). In particular the amount of VEGF
secretion was normalized to cell number (cells/mm2) and expressed
as amount of factor released in extracellular medium per 48 h. The
amount of VEGF produced by endothelial cells cultivated with sCD54s investigatedwith an inverted optical lightmicroscope; (A) cells beginning tomigrate and
lls cultivatedwith the addition of sCD54. The histogram shows the data mean± SD of the
resence of HUVEC-conditionedmediumcollected at p4 (CMP4), sCD54 and antibody direct
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results are shown in Fig. 5A–C. Capillary density produced by endothe-
lial cells seeded in matrigel, with the addition of sCD54, increased by
30% with respect to conventional procedure, as shown in histogram of
Fig. 5). In the presence of the anti-CD54 no tube formation was
observed.
4. Discussion
The development of cell-based therapies to assist/replace diseased
tissue is one of the most promising initiatives in regenerative medicine
[21]. Yet, a major challenge on our way towards the design of artiﬁcial
organs is controlling tissue vascularization to provide oxygen, nutrient
and to remove catabolites [18,19]. Precise knowledge of how tissue
microenvironments impacts on metabolism, proliferation and growth-
factor production will be essential for elucidation of microvessel forma-
tion [22]. Today, transplantation remains thepreferred clinical interven-
tion for the treatment of organ failures; nevertheless, owing to a
global shortage in donor organs, alternative strategies providing
bioengineered tissue for replacement of damaged, injured or missing
tissues are of high clinical priority [23]. An artiﬁcial tissue larger than a
few cubic millimeters cannot survive by simple diffusion and requires
formation of new blood capillaries to supply essential nutrients/oxygen
and enable connection to the host vascular system following implanta-
tion [23,24]. Likewise, tumors do not grow beyond a few millimeters
unless they become vascularized, in most cases by directing an
ingrowth of capillaries from adjacent blood vessels [25]. Therefore,
precise control of pro- and anti-angiogenic activities is of prime clinical
interest in current cancer therapy and tissue engineering initiatives
[26,27].
Although most of today's knowledge on vascularization regulatory
networks has been derived from in vitro monolayer cultures [28],
three-dimensional (3D) culture technologiesmay reveal further insight.
Current 3D models include formation of primitive vascular networks
in vitro by co culturing endothelial cells withmural cells or their precur-
sors [29,30]. The interplay between environmental and genetic impact
on tumor angiogenesis/proliferation is complex and remains largely
elusive [31]. A major challenge is to establish a generic cell culture
model mimicking tumor development and angiogenesis of a wide
variety of tumorigenic cell types [32,33].
5. Conclusion
In this study, we utilized a modiﬁed procedure for the isolation of
endothelial cells; to our knowledge, this isolation strategy is a ﬁrst
report that enabled a valid side-by-side assessment in the propagation
of isolated endothelial cells, whilst minimizing potential donor sample
variability. More importantly, this study is done with a goal towards
deﬁning and establishingmore robust culture methodologies to initiate
further development of suitable tissue engineered endothelial graft
alternatives.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcha.2015.01.004.
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